A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...

Colorectal cancer is preventable. Screening is the best way to improve chances of survival through early detection.

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

ABIVAX is a French biotech with a novel ulcerative colitis treatment in phase 3 trials. Click here to find out why I am ...

"2024 was transformative for OSE, marked by positive efficacy results, major partnerships, and accelerated preclinical ...

Body mass index did not impact the safety and efficacy of etrasimod in patients with ulcerative colitis, according to 2 studies.

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Approximately 1 in 26 women will be diagnosed with colorectal cancer in their lifetime. Despite this, many women may mistake ...

Diarrhea is one of the most common symptoms of ulcerative colitis. Sometimes it can be accompanied by blood and mucus. Treatments could help manage your symptoms. Ulcerative colitis (UC ...

You might have endoscopic surgery to remove abnormal areas in the lining of the stomach. Your doctor uses a long flexible tube (endoscope) with a tiny camera and light on the end to look inside your ...